Randall B. Riggs has over twenty-two (22) years of corporate strategy and business development experience within the pharmaceutical and biotechnology industries. From October 2007 to January 2017 he was the President & CEO of Advanced Cancer Therapeutics (ACT). As President and CEO of ACT, he created the infrastructure, in-licensed several novel anti-cancer products from third parties, raised over $14 million in capital and successfully completed a Phase I trial involving a first-in-class, first-in-man small molecule anti-cancer drug that selectively inhibits glucose uptake in cancer cells as a key nutrient as well as suppressing myeloid derived suppressor cells to reawaken the cancer patient’s immune system. From 2005 to October of 2007 he was the Senior Vice President of Corporate Development for BioCryst Pharmaceuticals and was responsible for approximately $1 billion dollars in strategic partnerships with multi-national firms including Hoffman-La Roche, Shionogi & Co., Mundipharma International LTD, and Green Cross Corp. Prior to BioCryst Pharmaceuticals, Mr. Riggs held the position of Senior Vice President of Corporate Development for Lexicon Pharmaceuticals (1998 – 2004). As a member of the Executive Management Team, $220 million was raised through their initial public offering in April 2000. In addition to his key role in Lexicon’s successful IPO, Mr. Riggs oversaw an increase in strategic partnership revenue from less than $2 million to over $60 million each year.
Mr. Riggs began his career in the pharmaceutical industry at Eli Lilly & Company in 1992 in sales and sales management and was quickly promoted to Manager in Corporate Business Development at corporate headquarters in Indianapolis. During this time, he played a leading role in the evaluation of several strategic acquisitions, product in-licensing opportunities, and establishment of several collaborations with biotechnology companies.
Mr. Riggs was elected in 2007 as the President of the Biotechnology Association of Alabama (BAA) in Birmingham, Alabama. Mr. Riggs received his Bachelor of Business Administration (BBA) in Management cum laude from Texas A&M University and his Master’s in Business Administration (MBA) in Finance from the University of Houston.
Gibson Oncology,LLC is composed of proven academic researchers and bio tech entrepreneurs who are excited to be developing effective and safer novel oncology drugs to treat resistant cancers with a focus on children.